文献速递系统性红斑狼疮

系统性红斑狼疮患者的临床表现、诊疗路径及获得专科诊疗的延迟:来自中西部狼疮网络(LUMEN)的研究

Clinical Presentation, Care Pathways, and Delays in Access to Specialized Care in Patients With Systemic Lupus Erythematosus: A Study From Lupus Midwest Network (LUMEN).
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-11-14

该研究纳入中西部狼疮网络登记的373例新发系统性红斑狼疮患者,评估从首次就诊至获得专科诊疗、确诊及开始治疗的时间。约25%患者获得专科诊疗延迟≥6个月,延迟与首次就诊时较少的狼疮表现、血液学表现或抗磷脂抗体相关,并与首次获得专科诊疗时损害(SDI≥1)相关。

要点

  • 373例新发系统性红斑狼疮患者中,93例(约25%)获得专科诊疗延迟≥6个月。
  • 延迟与首次就诊时少于两个狼疮领域表现相关(92% vs 72%,P < 0.001)。
  • 血液学领域(OR 1.71,95%CI 1.03-2.84)或抗磷脂抗体领域(OR 6.05,95%CI 2.46-14.88)与延迟相关。

核心结论

  • 患者获得诊疗的路径异质,四分之一患者获得系统性红斑狼疮专科诊疗延迟,延迟与疾病相关损害相关。
  • 较少的临床表现、血液学表现或抗磷脂抗体与延迟相关。

研究设计与样本

  • 纳入中西部狼疮网络登记的新发系统性红斑狼疮患者373例。
  • 估计从首次因系统性红斑狼疮临床表现就诊至获得专科诊疗、医生确诊及开始治疗的时间。
  • 延迟定义为获得专科诊疗≥6个月。
  • 比较有无延迟患者的系统性红斑狼疮表现、疾病活动度及系统性红斑狼疮国际协作组/美国风湿病学会损害指数(SDI)。
  • 采用逻辑回归模型评估与延迟的相关性。

主要发现

  • 获得系统性红斑狼疮专科诊疗的中位时间为1.1个月(95%CI 0.9-1.5)。
  • 确诊的中位时间为30.6个月(95%CI 18.9-48.1)。
  • 开始治疗的中位时间为4.7个月(95%CI 3.9-8.4)。
  • 约25%患者(373例中93例)经历获得专科诊疗延迟。
  • 延迟与首次系统性红斑狼疮相关就诊时较少的狼疮表现相关(少于两个狼疮领域:92% vs 72%,P < 0.001)。

关键数值与推荐

  • 延迟定义为获得专科诊疗≥6个月。
  • 损害指数采用系统性红斑狼疮国际协作组/美国风湿病学会损害指数(SDI)。
  • 延迟与SDI≥1相关(30% vs 7%,P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to characterize presentation and care pathways of patients with systemic lupus erythematosus (SLE), and delays in access to SLE-specialized care. METHODS: We included patients with incident SLE from the Lupus Midwest Network registry. Time from the first medical encounter for SLE clinical manifestation to access to SLE-specialized care, physician diagnosis, and treatment was estimated. Delays were defined as ≥6 months to access specialized care. We compared SLE manifestations, disease activity, and Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage indexes (SDI) between patients with and without delays. Logistic regression models assessed associations with delays. RESULTS: The study included 373 patients with SLE. The median time to access SLE-specialized care was 1.1 (95% confidence interval [CI] 0.9-1.5) months, time to diagnosis was 30.6 (95% CI 18.9-48.1) months, and time to treatment initiation was 4.7 (95% CI 3.9-8.4) months. Approximately 25% of patients (93 out of 373) experienced delays accessing specialized care, which were associated with fewer SLE manifestations at first SLE-related encounter (fewer than two SLE domains; 92% vs 72%, P < 0.001). Patients with mucocutaneous or musculoskeletal manifestations were less likely to experience delays, whereas hematologic (odds ratio [OR] 1.71, 95% CI 1.03-2.84) or antiphospholipid antibodies domains (OR 6.05, 95% CI 2.46-14.88) were associated with delays. Delays were associated with damage at first access to SLE-specialized care (SDI ≥1; 30% vs 7%, P < 0.001). CONCLUSION: Patients follow a heterogeneous pathway to receive care. One-fourth of patients experienced delays accessing SLE-specialized care, which was associated with disease-related damage. Fewer manifestations, hematologic manifestations, or antiphospholipid antibodies were associated with delays.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Sanchez-Rodriguez A, Meade-Aguilar JA, Yang JX, et al. Clinical Presentation, Care Pathways, and Delays in Access to Specialized Care in Patients With Systemic Lupus Erythematosus: A Study From Lupus Midwest Network (LUMEN). Arthritis Care Res (Hoboken). 2024. PMID: 39400527. doi:10.1002/acr.25445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。